mRNA 技术在登革热病毒疫苗开发中的机遇与挑战

arXiv - QuanBio - Other Quantitative Biology Pub Date : 2024-09-17 DOI:arxiv-2409.10805

Xiaoyang Liu, Daniel Salmon

{"title":"mRNA 技术在登革热病毒疫苗开发中的机遇与挑战","authors":"Xiaoyang Liu, Daniel Salmon","doi":"arxiv-2409.10805","DOIUrl":null,"url":null,"abstract":"Dengue virus (DENV) is a mosquito-borne virus with a significant human health\nconcern. With 390 million infections annually and 96 million showing clinical\nsymptoms, severe dengue can lead to life-threatening conditions like dengue\nhemorrhagic fever (DHF) and dengue shock syndrome (DSS). The only FDA-approved\nvaccine, Dengvaxia, has limitations due to antibody-dependent enhancement\n(ADE), necessitating careful administration. The recent pre-approval of TAK-003\nby WHO in 2024 highlights ongoing efforts to improve vaccine options. This\nreview explores recent advancements in dengue vaccine development, emphasizing\npotential utility of mRNA-based vaccines. By examining current clinical trial\ndata and innovations, we aim to identify promising strategies to address the\nlimitations of existing vaccines and enhance global dengue prevention efforts.","PeriodicalId":501219,"journal":{"name":"arXiv - QuanBio - Other Quantitative Biology","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Opportunities and challenges of mRNA technologies in development of Dengue Virus Vaccine\",\"authors\":\"Xiaoyang Liu, Daniel Salmon\",\"doi\":\"arxiv-2409.10805\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Dengue virus (DENV) is a mosquito-borne virus with a significant human health\\nconcern. With 390 million infections annually and 96 million showing clinical\\nsymptoms, severe dengue can lead to life-threatening conditions like dengue\\nhemorrhagic fever (DHF) and dengue shock syndrome (DSS). The only FDA-approved\\nvaccine, Dengvaxia, has limitations due to antibody-dependent enhancement\\n(ADE), necessitating careful administration. The recent pre-approval of TAK-003\\nby WHO in 2024 highlights ongoing efforts to improve vaccine options. This\\nreview explores recent advancements in dengue vaccine development, emphasizing\\npotential utility of mRNA-based vaccines. By examining current clinical trial\\ndata and innovations, we aim to identify promising strategies to address the\\nlimitations of existing vaccines and enhance global dengue prevention efforts.\",\"PeriodicalId\":501219,\"journal\":{\"name\":\"arXiv - QuanBio - Other Quantitative Biology\",\"volume\":\"41 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"arXiv - QuanBio - Other Quantitative Biology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/arxiv-2409.10805\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"arXiv - QuanBio - Other Quantitative Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/arxiv-2409.10805","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

登革热病毒（DENV）是一种由蚊子传播的病毒，严重危害人类健康。每年有 3.9 亿人感染登革热，其中 9600 万人出现临床症状，严重的登革热可导致出血性登革热（DHF）和登革热休克综合征（DSS）等危及生命的病症。美国食品和药物管理局批准的唯一疫苗登革热疫苗（Dengvaxia）存在抗体依赖性增强（ADE）的局限性，需要谨慎用药。最近，世卫组织于 2024 年预先批准了 TAK-003 疫苗，这凸显了目前为改进疫苗选择所做的努力。本综述探讨了登革热疫苗研发的最新进展，强调了基于 mRNA 的疫苗的潜在效用。通过研究当前的临床试验数据和创新，我们旨在确定有前景的战略，以解决现有疫苗的局限性并加强全球登革热预防工作。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Opportunities and challenges of mRNA technologies in development of Dengue Virus Vaccine

Dengue virus (DENV) is a mosquito-borne virus with a significant human health concern. With 390 million infections annually and 96 million showing clinical symptoms, severe dengue can lead to life-threatening conditions like dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The only FDA-approved vaccine, Dengvaxia, has limitations due to antibody-dependent enhancement (ADE), necessitating careful administration. The recent pre-approval of TAK-003 by WHO in 2024 highlights ongoing efforts to improve vaccine options. This review explores recent advancements in dengue vaccine development, emphasizing potential utility of mRNA-based vaccines. By examining current clinical trial data and innovations, we aim to identify promising strategies to address the limitations of existing vaccines and enhance global dengue prevention efforts.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

arXiv - QuanBio - Other Quantitative Biology

自引率

0.00%

发文量